The NYLIM CBRE Global Infrastructure Megatrends Term Fund (MEGI) is rated Buy due to its attractive 11% dividend yield and exposure to infrastructure sectors benefiting from AI and data center investments. The fund trades at about a 10% discount to NAV, providing potential upside if the discount narrows before its liquidation in 2033. However, its dividend depends heavily on realized capital gains, requiring sustained NAV growth to avoid erosion. Leverage at 22.5% increases both potential gains and risks, especially with rising interest rates that could raise borrowing costs and impact valuations. Investors should weigh these factors when considering MEGI's growth prospects and risks.
The NYLIM CBRE Global Infrastructure Megatrends Term Fund (MEGI) is noted here with Pluang's market data for context. For readers following US stocks on Pluang, as of Oct 13, 2026 22:41 WIB, out of 150 priced stocks, 59 rose and 90 fell. Notable movers include JBLU at USD 3.42 with a 1-day change of -5.66% and a typical hold time of 44 days, CAT at USD 755.55 down 5.48%, and MU at USD 937.94 down 5.17%.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
